is to supply the psychiatric/hospital care with EDOR®, a quantitative and objective measurement method for the identification of hyporeactive individuals among depressed patients. Clinical studies have demonstrated that these individuals are more vulnerable for suicide actions than others. With this most suicides and suicide attempts can be prevented, hospital care quality increased and costs reduced.
In March 2017, a three-year naturalistic non-blinded multicentre study, EUDOR-A, with 15 clinical centres from nine European countries, was finalized. More than 1 500 patients have been tested and followed up. Compared to earlier blind studies the suicide rate in EUDOR-A was significantly reduced, particularly in the hyporeactive group. These patients got substantially more comprehensive suicide preventive actions than patients belonging to the reactive group. With these results from EUDOR-A, the company decided to launch EDOR® to psychiatric specialists in Europe. We expect to focus our marketing work on the Nordic countries, Germany, Poland, Italy, Spain, the UK and France.
During the first few years, our marketing efforts will solely focus on specialist clinics that participate in the most important scientific conventions. These care centres are the key players on the market.
We focus our marketing efforts to early adopters at psychiatric clinical centres in larger cities in different European countries. The first objective is to have these clinics to implement EDOR as a routine operating procedure in the assessment of suicide risk. Later when they are more experienced with the procedure we will organize local workshops and seminars together with them to spread the information about the new method also to other psychiatric practitioners.